LearnGlossaryMarketStocksSuperinvestorsSign in

ORKA

Oruka Therapeutics, Inc.

Healthcare · $5.1B market cap

Verdict

We can't put a fair value on ORKA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-45.9% a year✗
Sales growth1105.3% a year✓
Free cash flow growth—?
Return on invested capital-22.8%✗

Follow ORKA

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds ORKA. In Q2 2026, 1 trimmed. Who we track

Viking Global Investors

Viking Global Investors · as of Q2 2026

$143.1M

1,503,478 shares

Moves in Q2 2026

Trimmed: Viking Global Investors

About Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works